New hope for GVHD patients: ruxolitinib tested as First-Line therapy
NCT ID NCT06660355
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 4 times
Summary
This study compares two drugs, ruxolitinib and prednisone, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication after bone marrow transplant. About 120 adults who need systemic therapy for cGVHD will be randomly assigned to receive one of the two drugs. The goal is to see if ruxolitinib works better than the standard steroid treatment at controlling the disease without needing additional therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Univ of Miami - Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
-
University of Kansas Cancer Center
RECRUITINGKansas City, Kansas, 66160, United States
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.